Oxford Science Enterprises

Porpoise Power is a company that specializes in developing tidal energy systems. Their innovative technology, inspired by the swimming mechanics of dolphins and whales, uses oscillating hydrofoils to harness the power of tidal streams. This unique approach allows the company to generate sustainable electricity at a relatively low cost and minimal environmental impact, even at medium tidal speeds.

Mode Labs specializes in developing and manufacturing low-cost, portable, real-time chemical sensors. Utilizing micron-scale quantum technology, their sensors are designed to speciate and quantify pollutants in natural waterways, offering lab-grade sensitivity with plug-and-play functionality. This enables clients to deploy robust, miniaturized, and scalable sensors remotely, providing continuous, real-time data.

Seloxium assists mining, refining, and industrial companies in achieving their ESG objectives by transforming wastewater into a sustainable resource. It employs advanced research to extract essential metals environmentally responsibly, reducing carbon footprint and preventing harmful metals from entering the environment.

Alloyed specializes in the research, development, and application of advanced metallic alloys. Founded in 2017 and headquartered in Begbroke, UK, the company focuses on creating optimized alloys and proprietary software for various industries including aerospace, automotive, defense, medical devices, energy, and consumer goods.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

Salience Labs develops hybrid photonic-electronic chips for AI applications. Founded on over a decade of research from Oxford and Münster universities, they specialize in silicon photonics to address AI data center infrastructure demands. Their flagship product is an optical switch designed to facilitate low-latency, high-bandwidth networking between compute nodes, accelerating job completion while reducing power consumption.

Neu Health develops a smartphone-based clinical platform for personalized care in Parkinson's disease and dementia. The platform uses AI to monitor symptoms, optimize condition management, reduce clinician burden, and improve patient outcomes.

FluoRok develops fluorinating molecules and scalable production processes to enable safer, more sustainable, and cost-effective fluorochemical manufacture. Its patented technology bypasses hydrofluoric acid in production, reducing hazards and environmental impact, and provides the agrochemical, pharmaceutical, and materials industries with cleaner fluorochemical solutions.

Iota Sciences Ltd. is a company focused on developing tools and technologies that utilize fluid shaping technologies to enhance drug discovery processes. Founded in 2016 and headquartered in Oxford, United Kingdom, the company specializes in creating fluidic mu-wells specifically designed for cell biology applications. Through its innovative approach, Iota Sciences aims to provide unique capabilities that facilitate advancements in the understanding and manipulation of cellular processes, thereby accelerating research and development in the pharmaceutical sector.

PQShield specializes in post-quantum cryptography solutions, safeguarding global technology infrastructures against future quantum computing threats. Founded in 2018 and based in Oxford, UK, the company offers hardware, software, and cloud-based implementations, leading standardization efforts worldwide.

Fractile is a technology company specializing in the development of advanced AI chips. Their innovative hardware is designed to significantly accelerate the inference process of large language models, which is currently hindered by the slow movement of network weights from memory to the chip. Fractile's groundbreaking approach, which integrates computation with memory, eliminates this bottleneck, enabling faster and more efficient AI model inference. This allows AI developers to run the largest language models more quickly and explore new capabilities in AI applications.

Amber Therapeutics specializes in developing advanced bioelectronic therapies that can sense and adapt, aiming to enhance clinical outcomes for patients with functional disorders of the peripheral nervous system.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Oxford Endovascular develops a neurovascular device to treat brain aneurysms. The device uses origami-inspired engineering with a laser-cut metal alloy that has shape-memory, enabling a catheter-delivered implant to expand into a tiny mesh tube that conforms to the vessel. By diverting blood flow away from the aneurysm, it promotes healing and reduces the risk of rupture.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Oxford Quantum Circuits develops quantum computing technology, aiming to tackle complex challenges such as climate change and drug discovery. Their fully functional quantum computer system enables businesses to explore innovative solutions and address global issues.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Prolific is a company that offers an online platform for researchers seeking to recruit survey participants efficiently and ethically. By connecting a diverse global audience, Prolific enables users to quickly submit surveys and specify their target demographics, facilitating the collection of high-quality psychological and behavioral data in a matter of minutes. The company's mission is to enhance accessibility to trustworthy data, ultimately supporting improved human knowledge and informed decision-making. Through its innovative approach, Prolific empowers researchers by providing a reliable and streamlined data collection process.

Beacon Therapeutics is a biotechnology company focused on developing gene therapies for rare retinal diseases that cause blindness. Utilizing its proprietary platform, Beacon aims to restore and improve vision in patients suffering from these debilitating conditions. Currently operating at the clinical stage, the company's primary focus lies within ophthalmology, with the goal of transforming lives by treating severe eye diseases.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

QuantrolOx specializes in developing automated machine learning-based control software for quantum technologies, focusing on the tuning, stabilization, and optimization of qubits. By providing robust software solutions, the company aids quantum scientists in achieving stable platforms for experimentation, which enhances the effectiveness of quantum computing applications. This innovative approach allows clients to utilize more cost-effective quantum infrastructure while efficiently implementing standard quantum computing technologies in their operations.

Mind Foundry Limited, incorporated in 2015 and based in Oxford, United Kingdom, develops enterprise software that enables organizations to extract valuable insights from their data. As an Oxford University company founded by leading experts in artificial intelligence and machine learning, Mind Foundry focuses on creating Responsible AI solutions designed to address significant real-world challenges across various sectors, including insurance, infrastructure, and defense. Their AI platform leverages advanced machine learning and algorithmic modeling techniques to help organizations tackle issues such as insurance fraud detection and complex signal processing. By promoting the responsible and transparent use of AI, Mind Foundry aims to foster collaboration between humans and artificial intelligence to address pressing global problems.

Quantum Motion Technologies is developing a universal quantum computer using Silicon-based CMOS processes. Its focus lies in creating scalable arrays of qubits, aiming to develop quantum computing architectures compatible with existing silicon processing methods.

Archangel Lightworks is a laser communications company specializing in the development of secure, wireless technology aimed at addressing the challenges of space-ground connectivity. The company focuses on creating innovative laser transmission systems that facilitate efficient communication within the aerospace sector. Its product offerings include space terminals designed for satellites, air terminals for drones and manned aircraft, and ground communications terminals. By providing these advanced solutions, Archangel Lightworks enables resilient connectivity that overcomes the limitations of traditional radio communications, which are often bandwidth-constrained and less secure.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Amber Therapeutics specializes in developing advanced bioelectronic therapies that can sense and adapt, aiming to enhance clinical outcomes for patients with functional disorders of the peripheral nervous system.

Oxford Ionics specializes in advanced quantum computing systems, focusing on trapped-ion technology. This enables scalable, efficient quantum chips produced via standard semiconductor methods, facilitating advancements in quantum computing and enhancing computational capabilities for complex problems.

BehaVR, LLC is a healthcare technology company founded in 2016 and based in Elizabethtown, Kentucky. The company specializes in developing digital therapeutics that leverage virtual reality to address behavioral health challenges, particularly in the context of chronic diseases. BehaVR's platform aims to enhance skills such as stress resilience, emotional regulation, and self-efficacy, enabling individuals to better manage their conditions, adhere to treatment plans, and ultimately improve their overall health outcomes. Through its innovative approach, BehaVR seeks to bridge the gap between behavioral health and chronic disease management.

Osler Diagnostics is a UK-based company focused on providing accessible and accurate health diagnostics. Founded in 2017 as a spin-off from the University of Oxford, the company has leveraged extensive research in portable diagnostic technologies, originally stemming from the development of the blood glucose sensor. Its flagship product, the Osler Origin, is a portable laboratory capable of delivering lab-quality diagnostics anytime and anywhere, enabling individuals to conduct tests for a variety of health biomarkers using just a drop of blood. This innovative approach aims to decentralize healthcare, making it easier for users to monitor their health and make informed decisions, ultimately supporting healthier and longer lives. Osler Diagnostics is headquartered in Oxford, UK, and aims to serve all major healthcare settings globally.

Util specializes in assessing and analyzing companies using a unique methodology that combines big data and machine learning. It quantifies and compares company performance across various stakeholder groups, converting these data into an 'annual value generated' metric. This enables responsible investors to evaluate both financial and non-financial returns on investment. Util's approach goes beyond traditional ESG metrics, providing a comprehensive view of companies as complex 'value generators'. It covers all listed securities and is used by investment managers seeking advanced analysis.

Nucleome Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, founded in 2019. The company focuses on decoding the "dark matter" of the human genome, which comprises over 95% of disease-linked genetic variants that have not yet been fully explored. By leveraging a unique platform that creates high-resolution three-dimensional genome structure maps and employs machine learning techniques, Nucleome aims to link these genetic variants to gene functions and map disease pathways. This innovative approach facilitates the functional validation of variants in primary cell types, enabling the discovery and development of novel therapeutics. Initially concentrating on lymphocytes and autoimmune diseases, Nucleome Therapeutics seeks to establish a robust pipeline of drug assets along with corresponding biomarkers to improve patient outcomes through genetically guided therapeutics.

Opsydia Limited, established in 2017 and based in Begbroke, UK, specializes in manufacturing advanced laser marking technology. This technology enables the creation of permanent, invisible structures such as serial numbers, images, and cryptographic data within transparent materials like diamonds, glass, polymers, and plastics without altering their surface or integrity. Opsydia's innovative solution aims to disrupt various industries by enhancing security, traceability, and authenticity in transparent materials.

Oxford Quantum Circuits develops quantum computing technology, aiming to tackle complex challenges such as climate change and drug discovery. Their fully functional quantum computer system enables businesses to explore innovative solutions and address global issues.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

ORCA Computing develops a photonic quantum computer designed to be scalable and flexible. Founded in 2019 and based in Oxford, United Kingdom, the company focuses on a photonic processor that uses quantum memories to store, synchronize, and buffer quantum operations, improving performance. Its modular, optical fiber–based architecture relies on telecoms photonics and off‑the‑shelf fiber and optical components to create a rack‑mounted platform. By exploiting photonic degrees of freedom, ORCA Computing aims to unlock new applications and accelerate innovation across industries.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

Salience Labs develops hybrid photonic-electronic chips for AI applications. Founded on over a decade of research from Oxford and Münster universities, they specialize in silicon photonics to address AI data center infrastructure demands. Their flagship product is an optical switch designed to facilitate low-latency, high-bandwidth networking between compute nodes, accelerating job completion while reducing power consumption.

OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.

Scenic Biotech develops genomics and immunotherapy technologies to unlock genetic suppressors as new drug targets for cancer and rare genetic diseases. The company focuses on disease suppressing genes that can counteract disease-causing mutations, enabling rapid identification and validation of novel targets for medicines. By leveraging genomics to identify modifiers that suppress or block the effects of harmful genes, Scenic Biotech aims to create disease-modifying therapies that address the genetic drivers of severe illnesses.

First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.

PQShield specializes in post-quantum cryptography solutions, safeguarding global technology infrastructures against future quantum computing threats. Founded in 2018 and based in Oxford, UK, the company offers hardware, software, and cloud-based implementations, leading standardization efforts worldwide.

Animal Dynamics is a company focused on developing advanced robotics inspired by the principles of evolutionary biomechanics. By leveraging recent advancements in analytical technology, the company evaluates high-performance animals to understand the mechanisms behind their efficiency and effectiveness. Animal Dynamics integrates fine engineering with a deep comprehension of these natural designs to create innovative robotic systems. Their platform combines insights from nature with cutting-edge materials science, microelectronics, and software engineering, resulting in a new generation of robotic vehicles. These vehicles have applications in various sectors, including agriculture for crop spraying and surveying, as well as in humanitarian aid, fire suppression, and military logistics. The company's mission emphasizes not only performance beyond current engineering capabilities but also a commitment to environmental protection through inspiration drawn from nature.

natcap is a nature intelligence company that provides report and act on impacts and dependencies on nature.

ONI specializes in super-resolution microscopy, making advanced imaging technology accessible to researchers worldwide. Its flagship product, the Nanoimager, offers easy access to techniques like dSTORM and PALM, enabling users to visualize molecules within living cells for enhanced biological research.

Alethiomics is a biotechnology company focused on pre-clinical research. It employs single-cell multi-omic technology to identify and develop innovative treatments for patients with blood cancers.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Rey is a membership-based, on-demand mental health company on a mission to revolutionize mental health and wellness by improving access to personalized services through technology.

Orbit Discovery is a biotechnology company specializing in peptide display technology to identify potential peptide drugs for chronic diseases. Its proprietary Orbit platform uses small beads linked with randomized peptide sequences to DNA, enabling screening tools for various disease types. The company focuses on establishing collaborative research platforms and internal drug discovery programs.

Omega Crop is a company that specializes in crop modeling, integrating geo-statistics with a comprehensive data ecosystem to enhance agricultural decision-making. By leveraging a diverse array of data sources, including satellites, drones, and hyper-local weather information, Omega Crop monitors and evaluates the performance of farming operations. Their technology offers detailed diagnostics of fields, enabling farmers to anticipate crop performance risks and address issues in real-time. This approach not only helps in making informed decisions but also creates opportunities for growers to optimize yields, ultimately contributing to global food production.

Oxford Endovascular develops a neurovascular device to treat brain aneurysms. The device uses origami-inspired engineering with a laser-cut metal alloy that has shape-memory, enabling a catheter-delivered implant to expand into a tiny mesh tube that conforms to the vessel. By diverting blood flow away from the aneurysm, it promotes healing and reduces the risk of rupture.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies and vaccines for infectious diseases and cancer. The company leverages a proprietary platform built around modified simian adenoviral vectors (ChAdOx1, ChAdOx2) and a Modified Vaccinia Ankara boost vector to stimulate potent CD8+ T cell responses, aiming to create durable immune protection. Its pipeline spans clinical and preclinical programs targeting solid tumors, viral infections, and prophylactic vaccines, with an emphasis on T-cell–oriented approaches that guide the immune system to address chronic infections, autoimmunity, and cancer.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

SpyBiotech Limited is a biotechnology company headquartered in Oxford, United Kingdom, founded in 2017. It develops a proprietary protein superglue technology that bonds antigens to viral or other particle carriers, creating what the company calls bonding vaccines. This platform enables research institutions and medical facilities to design and produce vaccines against infectious diseases and cancer more rapidly and with potentially improved efficacy. By simplifying the assembly of vaccine components, SpyBiotech aims to accelerate the development cycle and reduce time to clinical application.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Living Optics designs and develops a compact hyperspectral imaging camera and accompanying software to provide spectral imaging data across industrial, consumer, medical, and manufacturing applications. The system captures information beyond the capabilities of ordinary cameras, delivering accessible, portable hyperspectral imaging for use in research and product development. The company was founded in 2019 and is based in Oxford, United Kingdom.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

T-Cypher Bio is an early-stage biotechnology company focused on developing T-cell receptor (TCR)-based therapeutics. The company aims to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. T-Cypher addresses challenges in identifying therapeutically relevant targets and TCRs through its integrated platform, D-Cypher. This platform enables the generation of target screening libraries to identify functionally defined T-cell clones directly from disease tissues, providing an end-to-end approach to cell therapy development and patient treatment for a broad range of indications.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Refeyn Ltd develops and commercializes mass photometry technology for measuring the mass of single biomolecules in solution. The company offers instruments and accessories, including Refeyn One, which uses single-molecule light scattering to detect, image, and determine the mass of biomolecules in their native, unlabeled state. Its technology provides both research-grade tools and quality-control instruments for measuring biomolecules across a range of concentrations, enabling label-free mass measurement of individual molecules. Founded in 2018 and based in Oxford, United Kingdom, Refeyn focuses on delivering precise, rapid mass analysis to researchers studying proteins, nucleic acids, and other biomolecules.

ORCA Computing develops a photonic quantum computer designed to be scalable and flexible. Founded in 2019 and based in Oxford, United Kingdom, the company focuses on a photonic processor that uses quantum memories to store, synchronize, and buffer quantum operations, improving performance. Its modular, optical fiber–based architecture relies on telecoms photonics and off‑the‑shelf fiber and optical components to create a rack‑mounted platform. By exploiting photonic degrees of freedom, ORCA Computing aims to unlock new applications and accelerate innovation across industries.

PQShield specializes in post-quantum cryptography solutions, safeguarding global technology infrastructures against future quantum computing threats. Founded in 2018 and based in Oxford, UK, the company offers hardware, software, and cloud-based implementations, leading standardization efforts worldwide.

Oxford Ionics specializes in advanced quantum computing systems, focusing on trapped-ion technology. This enables scalable, efficient quantum chips produced via standard semiconductor methods, facilitating advancements in quantum computing and enhancing computational capabilities for complex problems.

Base Genomics is an epigenetics company developing TAPS (TET-assisted pyridine borane sequencing), a novel method for sequencing DNA methylation. Unlike traditional bisulfite sequencing, TAPS preserves DNA integrity and sequence complexity, enabling simultaneous epigenetic and genetic analysis from a single sample. This technology has applications in early cancer detection, biomarker discovery, and infectious disease diagnostics.

Oxford Flow designs, manufactures, and supplies pressure control equipment, including gas and fluid pressure regulators, water PRVs, silencers, and pilots, serving water, gas, marine, oil and gas, process, power, building services, and specialty applications. The company develops small, light, and reliable conventional valves that simplify systems and ensure continual potable water supplies while meeting standards for water quality and leakage control. It combines academic and industry expertise to develop practical, rigorously tested solutions that perform under harsh conditions, aiming to reduce total cost of ownership and environmental impact while improving reliability and energy efficiency. Based in Oxford, United Kingdom.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Quantum Motion Technologies is developing a universal quantum computer using Silicon-based CMOS processes. Its focus lies in creating scalable arrays of qubits, aiming to develop quantum computing architectures compatible with existing silicon processing methods.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

Living Optics designs and develops a compact hyperspectral imaging camera and accompanying software to provide spectral imaging data across industrial, consumer, medical, and manufacturing applications. The system captures information beyond the capabilities of ordinary cameras, delivering accessible, portable hyperspectral imaging for use in research and product development. The company was founded in 2019 and is based in Oxford, United Kingdom.

Perspectum develops digital health technologies that support clinicians in diagnosing and treating liver disease, diabetes, and cancer. Leveraging precision medicine through advanced imaging and genetics, the company provides AI-driven imaging tools and quantitative health assessments to enable early detection, accurate diagnosis, and targeted therapies. Its software-as-a-service platform delivers disease mapping, quantitative reports, and access to proprietary datasets for AI training, assisting physicians in clinical decision-making and helping pharmaceutical developers advance therapeutic programs. The team includes physicians, biomedical scientists, engineers, and technologists, and Perspectum aims to scale management of complex health problems across healthcare systems.

Animal Dynamics is a company focused on developing advanced robotics inspired by the principles of evolutionary biomechanics. By leveraging recent advancements in analytical technology, the company evaluates high-performance animals to understand the mechanisms behind their efficiency and effectiveness. Animal Dynamics integrates fine engineering with a deep comprehension of these natural designs to create innovative robotic systems. Their platform combines insights from nature with cutting-edge materials science, microelectronics, and software engineering, resulting in a new generation of robotic vehicles. These vehicles have applications in various sectors, including agriculture for crop spraying and surveying, as well as in humanitarian aid, fire suppression, and military logistics. The company's mission emphasizes not only performance beyond current engineering capabilities but also a commitment to environmental protection through inspiration drawn from nature.

OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.

Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.

Alloyed specializes in the research, development, and application of advanced metallic alloys. Founded in 2017 and headquartered in Begbroke, UK, the company focuses on creating optimized alloys and proprietary software for various industries including aerospace, automotive, defense, medical devices, energy, and consumer goods.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

YASA Motors Ltd. specializes in the manufacture of axial flux motors and generators tailored for electric and hybrid vehicles, as well as for various industrial applications. Established in 2009, the company produces a range of electric motors, including low-speed high-torque models and those designed for higher speed and power applications. YASA's innovative motor technology is particularly suited for sectors such as automotive, aerospace, marine, and construction equipment, where it addresses needs for traction, propulsion, and power generation. In addition to standard products, YASA offers custom motor solutions and consultancy services, which encompass electrical architecture design and thermal modeling. The company operates from its headquarters in Yarnton, United Kingdom, where it focuses on developing efficient, lightweight motors that meet the increasing global demand for reduced emissions and improved energy efficiency across multiple industries.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.

Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.

Oxford Semantic Technologies is a company founded in 2017 as a spin-out from the University of Oxford, specializing in the development of RDFox, an advanced knowledge graph and semantic reasoning engine. The company emerged from research initiated in 2011 at the University’s Computer Science Department, aimed at creating a high-performance solution for data-intensive applications. RDFox leverages patented modern computing techniques to provide rapid responses to complex queries, thus enabling enterprise applications for various prestigious partners. The engine is designed to harness the capabilities of modern multi-core architectures, simplifying the querying process for domain experts and reducing reliance on IT specialists. Additionally, RDFox includes features that explain how answers to queries are derived, enhancing clients' ability to validate their results and ensuring confidence in the insights generated.

Albus Health is a startup spun out from the University of Oxford. It has developed an intelligent nocturnal monitoring platform that offers personalized, passive, contactless, and objective monitoring of various symptoms and environmental metrics at home. The platform has been commercialized and is currently used by leading pharmaceutical companies to monitor nocturnal symptoms in clinical trials, with the potential to predict respiratory emergencies.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.

Alloyed specializes in the research, development, and application of advanced metallic alloys. Founded in 2017 and headquartered in Begbroke, UK, the company focuses on creating optimized alloys and proprietary software for various industries including aerospace, automotive, defense, medical devices, energy, and consumer goods.

Covatic develops broadcast personalization software and a consumer insights platform that enables on-device personalization for applications. Incorporated in 2016, the company is based in Birmingham, United Kingdom, with an additional office in London. Its platform provides an on-device software development kit that leverages trusted first-party and offline consented data to create contextual audience segments, helping media companies deliver relevant advertising while strengthening user trust and complying with privacy regulations.

Animal Dynamics is a company focused on developing advanced robotics inspired by the principles of evolutionary biomechanics. By leveraging recent advancements in analytical technology, the company evaluates high-performance animals to understand the mechanisms behind their efficiency and effectiveness. Animal Dynamics integrates fine engineering with a deep comprehension of these natural designs to create innovative robotic systems. Their platform combines insights from nature with cutting-edge materials science, microelectronics, and software engineering, resulting in a new generation of robotic vehicles. These vehicles have applications in various sectors, including agriculture for crop spraying and surveying, as well as in humanitarian aid, fire suppression, and military logistics. The company's mission emphasizes not only performance beyond current engineering capabilities but also a commitment to environmental protection through inspiration drawn from nature.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.